AdvocacyRSSMar 26
NORD, a major rare disease organization, is partnering with OpenEvidence to create AI-powered tools that help doctors and patients find reliable information about rare diseases. This partnership aims to make it easier for people worldwide to access trustworthy resources about their conditions and treatment options.
WHY IT MATTERSThis partnership could help patients with rare diseases get faster access to accurate, expert-reviewed information from their doctors, potentially reducing diagnostic delays and improving treatment decisions.
PolicyPUBMEDMar 26
France is creating a new type of healthcare worker called a Genomic Pathway Manager to help doctors order genetic tests for patients with rare diseases and cancer. These managers will make it easier for patients to get genetic testing by organizing the process and helping doctors understand when and how to use these tests. The goal is to make genetic testing available to more people across France starting in 2025.
WHY IT MATTERSIf you have a rare disease in France, this new system could help your doctor identify your condition faster through genetic testing, potentially leading to earlier diagnosis and treatment options.
PolicyPUBMEDMar 26
European countries are updating their rules for deciding whether new medicines work well and are worth the cost, especially for rare diseases and children. Because rare diseases affect few people and there's less testing data available, countries are making special adjustments to their evaluation methods. This study looked at how 28 European countries and the UK are handling these evaluations differently.
WHY IT MATTERSIf your country updates its health technology assessment rules, it could affect how quickly new rare disease treatments get approved and whether your insurance will cover them.
AdvocacyPUBMEDMar 26
This study looked at how patient groups led by people with rare diseases help fill gaps in education and awareness in Poland. Researchers interviewed 11 leaders of these patient groups to understand how they act as 'ambassadors' and 'advocates' to teach doctors, teachers, and the public about rare diseases. The findings show that patient advocacy groups play an important but often overlooked role in helping people understand and navigate rare diseases.
WHY IT MATTERSIf you have a rare disease, this research validates that patient-led advocacy groups are essential resources for getting accurate information and support when healthcare systems and professionals lack rare disease knowledge.
PolicyPUBMEDMar 26
People with inherited metabolic diseases (IMDs) in Latin America struggle to get life-saving medicines that are more available in wealthy countries. This article looks at why these medicines are hard to find in places like Chile and suggests ways to make them more accessible to everyone who needs them, no matter where they live.
WHY IT MATTERSIf you or a family member has an inherited metabolic disease in Latin America, this research directly addresses the barriers preventing you from accessing treatments that patients in high-income countries can obtain.
PolicyPUBMEDMar 26
Scientists and doctors are saying that the system for developing and selling medicines for rare diseases needs improvement. New discoveries in genetics have helped create targeted treatments, but these medicines are often very expensive and hard to access. The article calls on researchers, doctors, and other groups to work together to make rare disease medicines more affordable and available to patients who need them.
WHY IT MATTERSIf you or a loved one has a rare disease, this research highlights why medicines for your condition may be expensive or hard to get — and pushes for systemic changes that could improve your access to treatment options.